Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis

被引:100
作者
Kluger, HM
Dolled-Filhart, M
Rodov, S
Kacinski, BM
Camp, RL
Rimm, DL
机构
[1] Yale Univ, Sch Med, Sect Med Oncol WWW211, Dept Med, New Haven, CT 06520 USA
[2] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA
[3] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA
[4] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA
关键词
D O I
10.1158/1078-0432.CCR-0699-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Macrophage colony-stimulating factor-1 receptor (CSF-1R) is a transmembrane tyrosine kinase receptor, which is abnormally expressed in invasive breast cancer. Small cohort studies have demonstrated that increased expression of CSF-1R is associated with ipsilateral breast cancer recurrence. Correlation with survival has not been reported. Our aim was to further evaluate the role of CSF-1R in breast cancer, by studying the expression of CSF-1R in a large cohort of clinical specimens. Experimental Design: Tissue microarrays containing 301 node-negative and 280 node-positive cases were used. Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data. Results: CSF-1R expression was strongly associated with nodal status. Of the node-negative cases, 114 (38.9%) stained positive for CSF-1R, whereas 189 (67.5%) of the node-positive cases expressed CSF-IR (P < 0.0001). CSF-IR expression is also associated with larger tumor size (P = 0.02). Positive staining was strongly associated with decreased survival (P = 0.0003). Among node-negative patients, CSF-1R expression was associated with decreased overall survival (P = 0.045), whereas among node-positive patients, it was not (P = 0.47). In multivariate analysis, CSF-1R was not independent of nodal status as a predictor of survival. Conclusions: CSF-1R expression is a strong predictor of poor outcome in nonmetastatic breast cancer. It is significantly more frequently expressed in patients with nodal involvement. Among the node-negative patients, it has a stronger association with survival than among the nodepositive patients. Our findings support other preclinical findings that CSF-1R may be involved in local invasion and metastasis. Thus, this receptor may be an effective target for therapeutic agents.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 22 条
  • [1] BAIOCCHI G, 1991, CANCER, V67, P990, DOI 10.1002/1097-0142(19910215)67:4<990::AID-CNCR2820670422>3.0.CO
  • [2] 2-8
  • [3] Camp RL, 2003, CANCER RES, V63, P1445
  • [4] EXPRESSION OF COLONY-STIMULATING FACTOR-I IN THE HUMAN UTERUS AND PLACENTA
    DAITER, E
    PAMPFER, S
    YEUNG, YG
    BARAD, D
    STANLEY, ER
    POLLARD, JW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (04) : 850 - 858
  • [5] Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594
  • [6] DOLLEDFILHART M, 2002, PRINC PRACTICES ONCO, V16, P1
  • [7] ISOLATION OF V-FMS AND ITS HUMAN CELLULAR HOMOLOG
    HEISTERKAMP, N
    GROFFEN, J
    STEPHENSON, JR
    [J]. VIROLOGY, 1983, 126 (01) : 248 - 258
  • [8] Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression
    Ide, H
    Seligson, DB
    Memarzadeh, S
    Xin, L
    Horvath, S
    Dubey, P
    Flick, MB
    Kacinski, BM
    Palotie, A
    Witte, ON
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) : 14404 - 14409
  • [9] THE CYTOKINE CSF-1 (M-CSF) EXPRESSED BY ENDOMETRIAL CARCINOMAS INVIVO AND INVITRO, MAY ALSO BE A CIRCULATING TUMOR-MARKER OF NEOPLASTIC DISEASE-ACTIVITY IN ENDOMETRIAL CARCINOMA PATIENTS
    KACINSKI, BM
    CHAMBERS, SK
    STANLEY, ER
    CARTER, D
    TSENG, P
    SCATA, KA
    CHANG, DHY
    PIRRO, MH
    NGUYEN, JT
    ARIZA, A
    ROHRSCHNEIDER, LR
    ROTHWELL, VM
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (03): : 619 - 626
  • [10] HIGH-LEVEL EXPRESSION OF FMS PROTO-ONCOGENE MESSENGER-RNA IS OBSERVED IN CLINICALLY AGGRESSIVE HUMAN ENDOMETRIAL ADENOCARCINOMAS
    KACINSKI, BM
    CARTER, D
    MITTAL, K
    KOHORN, EI
    BLOODGOOD, RS
    DONAHUE, J
    DONOFRIO, L
    EDWARDS, R
    SCHWARTZ, PE
    CHAMBERS, JT
    CHAMBERS, SK
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (04): : 823 - 829